166 related articles for article (PubMed ID: 15784340)
21. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
[TBL] [Abstract][Full Text] [Related]
22. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
[TBL] [Abstract][Full Text] [Related]
23. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
Detrait ER; Carr GV; Weinberger DR; Lamberty Y
Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
[TBL] [Abstract][Full Text] [Related]
24. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
Haasio K; Lounatmaa K; Sukura A
Exp Toxicol Pathol; 2002 Jul; 54(1):9-14. PubMed ID: 12180806
[TBL] [Abstract][Full Text] [Related]
25. Tissue and interspecies comparison of catechol-
Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
[TBL] [Abstract][Full Text] [Related]
26. Effects of entacapone and tolcapone on mitochondrial membrane potential.
Haasio K; Koponen A; Penttilä KE; Nissinen E
Eur J Pharmacol; 2002 Oct; 453(1):21-6. PubMed ID: 12393055
[TBL] [Abstract][Full Text] [Related]
27. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.
Lautala P; Ethell BT; Taskinen J; Burchell B
Drug Metab Dispos; 2000 Nov; 28(11):1385-9. PubMed ID: 11038168
[TBL] [Abstract][Full Text] [Related]
28. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
Haasio K; Nissinen E; Sopanen L; Heinonen EH
J Neural Transm (Vienna); 2002 Nov; 109(11):1391-401. PubMed ID: 12454735
[TBL] [Abstract][Full Text] [Related]
29. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
Longo DM; Yang Y; Watkins PB; Howell BA; Siler SQ
CPT Pharmacometrics Syst Pharmacol; 2016 Jan; 5(1):31-9. PubMed ID: 26844013
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Thiffault C; Langston JW; Di Monte DA
Exp Neurol; 2003 Sep; 183(1):173-9. PubMed ID: 12957500
[TBL] [Abstract][Full Text] [Related]
31. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
[TBL] [Abstract][Full Text] [Related]
32. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L
Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846
[TBL] [Abstract][Full Text] [Related]
35. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
[TBL] [Abstract][Full Text] [Related]
36. Practical issues with COMT inhibitors in Parkinson's disease.
Waters C
Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
Nissinen E; Lindén IB; Schultz E; Pohto P
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
[TBL] [Abstract][Full Text] [Related]
38. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.
Tuomainen P; Törnwall M; Männistö PT
Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199
[TBL] [Abstract][Full Text] [Related]
39. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
Grünig D; Felser A; Bouitbir J; Krähenbühl S
Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
[TBL] [Abstract][Full Text] [Related]
40. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
